Alana Young
Medical · Randolph, NJNPI 1326423328
Payments from drug & device makers
Across 272 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$540
- Novo Nordisk$503
- Boehringer Ingelheim$455
- Pfizer$314
- Lilly USA, LLC$281
- Takeda Pharmaceuticals U.S.A., Inc.$275
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,204100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 48 | $540 |
| Novo Nordisk | 32 | $503 |
| Boehringer Ingelheim | 29 | $455 |
| Pfizer | 20 | $314 |
| Lilly USA, LLC | 18 | $281 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $275 |
| AstraZeneca | 16 | $264 |
| Exact Sciences | 7 | $173 |
| Otsuka America Pharmaceutical, Inc. | 9 | $170 |
| GSK | 11 | $154 |
| Axsome Therapeutics, Inc. | 9 | $146 |
| Johnson & Johnson | 8 | $128 |
| Merck | 8 | $117 |
| Astellas Pharma US Inc | 5 | $108 |
| Novartis | 6 | $81 |
| Abbott | 3 | $67 |
| Bayer | 3 | $63 |
| Idorsia Pharmaceuticals US Inc | 3 | $49 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $47 |
| IBSA Pharma Inc. | 2 | $42 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Corium, LLC | 2 | $35 |
| Seqirus USA Inc | 2 | $34 |
| Althera Pharmaceuticals LLC | 2 | $33 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Cranial Technologies, Inc | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Optinose US, Inc. | 1 | $15 |
| Bausch Health US, LLC | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
How this compares
$4,204 in reported general payments places this provider in the 85th percentile of 573 medical providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 13 | $61,628 |
| OzempicSemaglutide | 20 | $14,806 |
| Levothyroxine Sodium | 38 | $1,940 |
| Rosuvastatin Calcium | 48 | $778 |
| Atorvastatin Calcium | 38 | $288 |
| Fluticasone Propionate | 14 | $254 |
| Clonazepam | 22 | $216 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $207 |
| Escitalopram Oxalate | 13 | $187 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 12 | $158 |
| Lisinopril | 31 | $157 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $128 |
| Metoprolol Succinate | 15 | $89 |
| Amlodipine Besylate | 13 | $84 |
| Omeprazole | 12 | $78 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $503 | $14,80620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 573 medical providers in New Jersey.
Other medical in Randolph
- Cristin KellyRandolph$6K
- Alison PietrasBrick$1.2M
- Shannon WelnerVerona$176K
- Christinna DelgenioColts Neck$114K
- Anita FoxVerona$17K
- Therese CasasKinnelon$16K
- Joseph CollettiLinwood$16K
- Melissa MiaoKearny$14K
- Gabriela Plesek-AndiaVerona$13K
- Stephanie PhillipsMarlton$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.